This post was written by Paul Sheives. FDA has completed the “New Molecular Entity Postmarketing Safety Evaluation Pilot Program” that began in January, 2007. This pilot program undertook a systematic and collaborative review of the safety profiles of selected approved new molecular entities that have been marketed for varying lengths of time.  The pilot program determined the value of such a systematic review, noting the substantial effort and personnel resources involved.